All Releases
 |
Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
Jun 18, 2009
|
8.1 KB |
|
| |
SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. British Summer Time (4:30 am Eastern Time, 1:30 a.m. Pacific Time) at the Andaz Hotel in Lon...
|
|
Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
Jun 17, 2009
|
9.4 KB |
|
| |
SAN DIEGO, June 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Arena stockholder, to provide Arena with $100 million in funding through a credit facility...
|
|
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
Jun 6, 2009
|
17.1 KB |
|
| |
NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy o...
|
|
Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Jun 5, 2009
|
8.1 KB |
|
| |
SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Robert E....
|
|
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
Jun 1, 2009
|
9.0 KB |
|
| |
SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes A...
|
|
Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
May 13, 2009
|
8.2 KB |
|
| |
SAN DIEGO, May 13, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eastern Time (7:10 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston...
|
|
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
May 11, 2009
|
16.1 KB |
|
| |
SAN DIEGO, May 11, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2009.
Arena reported a net loss allocable to common stockholders in the first quarter of 2009 of $50.6 million, or $0.68 per share, compared to a net loss ...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
May 5, 2009
|
8.3 KB |
|
| |
SAN DIEGO, May 5, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoff...
|
|
Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
Mar 30, 2009
|
19.7 KB |
|
| |
SAN DIEGO, March 30, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight ...
|
|
Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Mar 29, 2009
|
8.5 KB |
|
| |
SAN DIEGO, March 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight a...
|
|
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Mar 23, 2009
|
7.2 KB |
|
| |
SAN DIEGO, March 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its com...
|
|
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results
Mar 12, 2009
|
16.2 KB |
|
| |
SAN DIEGO, March 12, 2009, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2008.
Arena reported a net loss allocable to common stockholders in the fourth quarter of 2008 of $62.5 million, or $0.84 per share, an...
|
|
Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
Mar 5, 2009
|
8.4 KB |
|
| |
SAN DIEGO, March 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2008 financial results after the NASDAQ Global Market closes on Thursday, March 12, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, an...
|
|
Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
Feb 18, 2009
|
8.1 KB |
|
| |
SAN DIEGO, Feb 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of a Phase 2 clinical trial of an orally administered niacin receptor agonist drug candidate being developed by Merck & Co., Inc., under its collaboration with Arena to treat atherosclerosis. Agonists o...
|
|
Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
Feb 4, 2009
|
8.1 KB |
|
| |
SAN DIEGO, Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BIO CEO & Investor Conference on February 10, 2009 at 1:45 p.m. Eastern Time (10:45 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief, Arena's ...
|
|
Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Jan 8, 2009
|
8.2 KB |
|
| |
SAN DIEGO, Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on January 14, 2009 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time) at the Westin St. Francis Hotel in San Francisco. J...
|
|
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Dec 15, 2008
|
9.7 KB |
|
| |
SAN DIEGO, Dec 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the gluc...
|
|
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Dec 9, 2008
|
8.2 KB |
|
| |
SAN DIEGO, Dec 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary...
|
|
Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
Dec 8, 2008
|
8.3 KB |
|
| |
SAN DIEGO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will host a Research and Development
Day on Monday, December 15, 2008, beginning at approximately 12:00 p.m.
Eastern Time (9:00 a.m. Pacific Time). Speakers, including Jack Lief,
President and Chief Execut...
|
|
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Dec 8, 2008
|
11.9 KB |
|
| |
SAN DIEGO, Dec 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today publication of the Phase 2b clinical trial
results of lorcaserin, its novel drug candidate for the treatment of obesity,
in the December 4, 2008 issue of Obesity, the official peer reviewed journal
of The Obesity ...
|
|
|
